Suppr超能文献

日本人群中接受根治性前列腺切除术治疗的小体积或不显著前列腺癌的生化结局。

Biochemical outcome of small-volume or insignificant prostate cancer treated with radical prostatectomy in Japanese population.

机构信息

Department of Urology, Hirosaki University Graduate School of Medicine, 5 Zaifu Cho, Hirosaki, 036-8562, Japan.

出版信息

Int J Clin Oncol. 2012 Apr;17(2):119-23. doi: 10.1007/s10147-011-0267-6. Epub 2011 Jun 16.

Abstract

BACKGROUND

We investigated the biochemical outcome of small-volume prostate cancers [tumor volume (TV) < 0.5 mL, SVCa] and insignificant prostate cancers (TV <0.5 mL without any Gleason pattern 4/5 elements, InsigCa) treated with radical prostatectomy.

METHODS

Between April 2000 and May 2010, 609 patients with prostate cancer underwent radical prostatectomy at Hirosaki University Graduate School of Medicine. Of these, 237 were excluded from the study because of preoperative adjuvant therapy. The remaining 372 patients underwent routine histopathological and TV evaluations. Biochemical recurrence (BCR) was defined as the presence of prostate-specific antigen (PSA) levels greater than 0.2 ng/mL after prostatectomy.

RESULTS

The median patient age was 68 years (range 48-78 years) and the median preoperative PSA level was 7.50 ng/mL. The mean follow-up period was 45.9 months and the mean TV was 2.16 mL. Sixty patients (16.3%) had SVCa and 14 (3.7%) had InsigCa. The 5-year BCR-free survival rate for patients with SVCa was 67.3% and that for patients with a TV of 0.5 or greater was 87.1%. A significant difference was seen between the groups using the log-rank test (P = 0.008). We could not identify any BCR in patients with InsigCa.

CONCLUSION

Despite the limited number of cases, patients with InsigCa did not develop BCR whereas 12.9% of those with SVCa developed BCR after radical prostatectomy within 5 years. Accurate prediction of the biochemical outcome of SVCa remains difficult and further studies are needed.

摘要

背景

我们研究了小体积前列腺癌(肿瘤体积[TV] < 0.5 毫升,SVCa)和非显著前列腺癌(TV < 0.5 毫升且无任何 Gleason 模式 4/5 成分,InsigCa)经根治性前列腺切除术治疗后的生化结局。

方法

在 2000 年 4 月至 2010 年 5 月期间,609 例前列腺癌患者在弘前大学研究生院医学部接受根治性前列腺切除术。其中 237 例因术前辅助治疗而被排除在研究之外。其余 372 例患者接受了常规的组织病理学和 TV 评估。生化复发(BCR)定义为前列腺切除术后前列腺特异性抗原(PSA)水平大于 0.2ng/mL。

结果

患者年龄中位数为 68 岁(范围 48-78 岁),术前 PSA 水平中位数为 7.50ng/mL。平均随访时间为 45.9 个月,平均 TV 为 2.16mL。60 例(16.3%)患者为 SVCa,14 例(3.7%)患者为 InsigCa。SVCa 患者的 5 年 BCR 无复发生存率为 67.3%,TV 为 0.5 或更大的患者为 87.1%。对数秩检验显示两组之间有显著差异(P = 0.008)。我们在 InsigCa 患者中未发现任何 BCR。

结论

尽管病例数量有限,但 InsigCa 患者在根治性前列腺切除术后 5 年内未发生 BCR,而 SVCa 患者中有 12.9%发生了 BCR。准确预测 SVCa 的生化结局仍然困难,需要进一步研究。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验